Skip to content

Stability data on Pfizer COVID-19 vaccine support 5-day storage at point of use

September 15, 2020

At its Investor Day event, Pfizer (PFE -0.1%) reviewed its pipeline of 89 projects spread across six therapeutic areas. Four programs are in registration and 23 are in Phase 3 development.

27 key programs highlighted.

Revenue CAGR of at least 6% over the next five years.

Highlights pertaining to COVID-19:


Stability data on BNT162b2 supports five-storage at refrigerated (2-8 °C) temperature.

Phase 1 data two weeks after the second shot showed neutralizing geometric mean titers higher than convalescent sera.

Limited blinded tolerability data from ongoing Phase 3 study showed mild-to-moderate tolerability profile.

Application filed with FDA to expand Phase 3 enrollment to ~44K subjects, allowing for recruitment of new populations. Current enrollment is north of 29K.

Data readout on efficacy likely by end of October.

Protease inhibitor:

Initiated a Phase 1b study of PF-07304814, an intravenously administered phosphate prodrug that metabolizes into the active compound PF-00835321 which has demonstrated to be a very potent inhibitor of the SARS-Cov2 3CL protease in preclinical studies.

Related ticker: BioNTech SE (BNTX -1.3%)

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: